immatics

Bristol Myers culls cell therapy deals with 2 biotechs

BMS has terminated cell therapy pacts with two biotechs amid "portfolio prioritization efforts” within the pharma, one of the affected companies said.

Gabrielle Masson Dec 16, 2024 11:19am

Immatics leaps into phase 3 on strength of early-stage PFS data

Oct 10, 2024 8:49am

ESMO: Bristol Myers axes Immatics' bispecific after $150M bet

Sep 16, 2024 6:59am

With $1.7B Immatics deal, Moderna bets again on cancer vaccines

Sep 11, 2023 8:12am

Immatics' stock soars on PRAME prospect's solid tumor data

May 3, 2023 9:35am

GSK severs Immatics partnership in further T-cell retreat

Nov 17, 2022 11:00am